SG Americas Securities LLC significantly increased its investment in Hologic, Inc. by acquiring an additional 78,627 shares during the third quarter of 2023. This raised the firm’s total holdings to 83,358 shares, reflecting a remarkable increase of 1,662%. As of the end of September, SG Americas’ stake in the medical equipment provider was valued at approximately $5.6 million.
A number of other institutional investors have also adjusted their positions in Hologic. Chung Wu Investment Group LLC entered the market with a new stake valued at around $26,000 in the second quarter. Meanwhile, Caitong International Asset Management Co. Ltd boosted its holdings by 193.6%, acquiring 273 additional shares to reach a total of 414 shares, with a current valuation of $27,000. Similarly, SJS Investment Consulting Inc. increased its stake by 341.5%, holding 468 shares worth $32,000 after purchasing an additional 362 shares during the same quarter. Other notable investments included Loomis Sayles & Co. L P, which acquired a stake worth $33,000, and Cromwell Holdings LLC, which raised its position by 307.0% to own 578 shares valued at $38,000. Overall, hedge funds and institutional investors currently own 94.73% of Hologic’s stock.
Insider Transactions and Earnings Report
In related news, Hologic’s Director, Christiana Stamoulis, sold 7,402 shares on October 20, 2023, at an average price of $73.07, totaling approximately $540,864. Following this transaction, Stamoulis holds 47,336 shares in the company, valued at around $3.46 million, representing a decrease of 13.52% in her holdings. Currently, company insiders own just 1.88% of Hologic’s stock.
Hologic released its latest earnings report on November 3, 2023, revealing an earnings per share (EPS) of $1.13, surpassing analysts’ expectations of $1.10 by $0.03. The company reported revenues of $1.05 billion for the quarter, which exceeded the consensus estimate of $1.03 billion. Hologic also noted a net margin of 13.80% and a return on equity of 20.13%. Compared to the same quarter last year, revenue increased by 6.2%, and the firm’s EPS rose from $1.01 to $1.13. Analysts project that Hologic will achieve an EPS of $4.28 for the current fiscal year.
Analyst Ratings and Future Outlook
Several research analysts have recently provided insights on Hologic’s stock. Raymond James Financial downgraded shares from a “moderate buy” to a “hold” rating on October 22, 2023. JPMorgan Chase & Co. maintained a “neutral” rating, setting a price target of $78.00. BNP Paribas Exane also revised its rating from “outperform” to “neutral,” with a price objective of $79.00. Conversely, Argus raised its target price from $80.00 to $90.00 and issued a “buy” rating on September 19, 2023. Weiss Ratings reaffirmed a “hold (c)” rating on October 31, 2023. Currently, four analysts rate Hologic as a buy, while fourteen maintain a hold rating, resulting in a consensus rating of “hold” with an average price target of $79.29.
Founded in 1985 and headquartered in Marlborough, Massachusetts, Hologic, Inc. specializes in women’s health through innovative medical technology. The company develops diagnostic products, imaging systems, and surgical solutions aimed at detecting, diagnosing, and treating diseases, particularly in areas such as breast and skeletal health, gynecological conditions, and molecular diagnostics. Its diverse product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment, and molecular assays for infectious disease and oncology applications.
For those interested in further investment insights, detailed reports on Hologic and its performance can be accessed through investment platforms like HoldingsChannel.com.
